Evidence on Covalon's New ColActive Plus
Powder presented at the Symposium on Advanced Wound Care
MISSISSAUGA, ON, Nov. 1, 2022
/CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon")
(TSXV: COV) (OTCQX: CVALF), an advanced medical technologies
company, today announced that its newest advanced wound care
product, ColActive Plus Powder, was showcased in a case study
presentation at the Symposium on Advanced Wound Care (SAWC), from
October 13 to 16, 2022 in
Las Vegas. The study, conducted by
Dr. Alton Johnson Jr., DPM, FACPM,
DABPM, CWSP, at University of
Michigan School of Medicine, demonstrates the efficacy of
ColActive Plus Powder in treating chronic non-healing wounds.
"I've had success using the ColActive Plus Powder to close
challenging stalled wounds. It's applicable to a range of wound
types, offering the benefits of collagen in an advanced formulation
suitable for chronic or acute wounds", states Dr. Johnson. "It's a
unique product, the only collagen-based powder that is available
with or without an antimicrobial."
Chronic, hard-to-heal wounds fail to advance through the phases
of healing in an orderly and timely manner, often becoming stalled
in the inflammatory phase. Imbalances in important cellular
mediators for healing perpetuate the cycle of chronicity, which can
lead to severe complications such as infection or amputation, which
have grave consequences on overall quality of life. ColActive Plus
Collagen Powder was uniquely designed to optimize the wound
environment while supporting native collagen and connective tissue
growth to help clinicians break the cycle of chronicity.
"In just a short time on the market, ColActive Plus Powder has
become known as a "closer" of challenging wounds. The positive
outcomes we're seeing from clinicians like Dr. Johnson continue to
drive growth of this new and unique product and importantly, remind
us of the impact it can have on patients suffering from chronic
wounds," says Brian Pedlar, CEO of
Covalon.
Case Study Summary
- An 83-year-old patient with peripheral arterial disease
underwent metatarsal toe amputation which resulted in non-healing
wounds.
- The post-amputation surgical wounds failed to heal over several
months with use of a competitive collagen/Oxidized Regenerated
Cellulose product.
- Treatment with weekly pulse lavage and ColActive Plus Powder
resulted in the chronic post-amputation wounds being closed within
28 days, remaining healed to date.
- Dr. Alton Johnson Jr. concluded
that the use of the novel powder preparation of the ColActive
formulation, in combination with pulse lavage, initiated and
progressed the healing of the patient's chronic wounds rapidly, in
addition to being simple to use as part of the existing treatment
plan.
For further details, please refer to the case study poster.
Covalon's advanced wound care solutions include the
following:
- ColActive® Plus Powder - Collagen wound filler that
supports native collagen and connective tissue growth within the
wound bed, while also stimulating cellular processes essential for
wound healing. Allows for optimal moisture balance. Excellent
solution for wounds of irregular shape or wounds in challenging
locations
- ColActive® Plus Powder Ag - Collagen wound filler with
antimicrobial ionic silver to prevent bacterial colonization within
the product, thus minimizing the risk of infection.
Healthcare providers who are interested in learning more about
Covalon's solutions can visit www.covalon.com or follow
Covalon on LinkedIn, Facebook, Instagram or Twitter.
About Covalon
Covalon Technologies Ltd. is a
researcher, developer, manufacturer, and marketer of
patent-protected medical products that improve patient outcomes and
save lives in the areas of advanced wound care, infection
management and surgical procedures. Covalon leverages its patented
medical technology platforms and expertise in two ways: (i) by
developing products that are sold under Covalon's name; and (ii) by
developing and commercializing medical products for other medical
companies under development and license contracts. The Company is
listed on the TSX Venture Exchange, having the symbol COV and
trades on the OTQX Market under the symbol CVALF. To learn more
about Covalon, visit our website at www.covalon.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" or variations of such words and
phrases or state that certain actions, events or results "may",
"could", "would", "might", "will" or "will be taken", "occur" or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
three and nine months ended June 30,
2022, which is available on the Company's profile at
www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events or
otherwise, except as required by law.
Website: https://covalon.com/
Twitter: @covalon
View original content to download
multimedia:https://www.prnewswire.com/news-releases/closing-chronic-wounds-with-collagen-powder-university-of-michigan-case-study-demonstrates-the-efficacy-of-colactive-plus-powder-in-resolving-non-healing-wounds-301664888.html
SOURCE Covalon Technologies Ltd.